<DOC>
	<DOC>NCT01723904</DOC>
	<brief_summary>This study is to investigate the safety and efficacy of Rotigotine add-on therapy with low doses of Pramipexole or Ropinirole in patients with advanced-stage Parkinson's Disease (PD) who have insufficient response to L-dopa and low doses dopamine receptor agonists.</brief_summary>
	<brief_title>A Phase 3b, Open-Label, Safety and Efficacy Study of Rotigotine as Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Ropinirole</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<mesh_term>N 0437</mesh_term>
	<criteria>Subject is male or female, aged ≥ 30 and &lt; 80 years at informed consent Subject has idiopathic Parkinson's Disease, of more than 3 years duration, as defined by the cardinal sign, bradykinesia, and the presence of at least 1 of the following: resting tremor, rigidity, impairment of postural reflexes, and without any known or suspected cause of Parkinsonism Subject has motor fluctuations such as wearing, dyskinesia Subject has experienced nocturias for at least 3 nights within 7 days prior to Baseline Subject is taking levodopa (LDOPA, immediate and/or controlled release) in combination with benserazide or carbidopa and has been on a stable dose of LDOPA for at least 28 days prior to Baseline (Visit 2) Subject is taking a nonergot dopamine agonist (pramipexole ≤ 1.5 mg/day or ropinirole ≤ 6.0 mg/day) and has been on a stable dose of nonergot dopamine agonist for at least 28 days prior to Baseline (Visit 2) Subject is receiving therapy with tolcapone or budipine Subject is receiving therapy with one of the following drugs either concurrently or within 28 days prior to Baseline (Visit 2): alphamethyl dopa, metoclopramide, reserpine, neuroleptics (except specific atypical neuroleptics: olanzapine, ziprasidone, aripiprazole, clozapine, quetiapine), monoamine oxidase A (MAOA) inhibitors, methylphenidate, or amphetamine Subject has a history of symptomatic (not asymptomatic) orthostatic hypotension within the 6 months prior to Baseline (Visit 2) Subject has a known hypersensitivity to any components of the study medication, such as a history of significant skin hypersensitivity to adhesives, known hypersensitivity to other transdermal medications, or has unresolved contact dermatitis Subject is pregnant or nursing, or is of childbearing potential (ie, is (i) not surgically sterile, or, (ii) not using adequate birth control methods [including at least one barrier method] or, (iii) not sexually abstinent, or (iv) not at least 2 years post menopausal) Subject had a previous diagnosis of narcolepsy, sleep apnea syndrome, restless legs syndrome, or periodic limb movement disorder</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Rotigotine</keyword>
	<keyword>Neupro</keyword>
</DOC>